Ublituximab shows promise for Long-Term MS control in large extension trial

NCT ID NCT04130997

Ongoing Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track relapse rates and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ublituximab (a monoclonal antibody targeting CD20)

What this could lead to

If successful, this study could confirm ublituximab as a safe and effective long-term treatment to reduce relapses in people with relapsing multiple sclerosis.

What could go wrong

This is an extension study, so participants already know they tolerate ublituximab. However, long-term risks or reduced effectiveness over time are still possible. The study is not designed to prove a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS (RMS)

Contacts and locations

Show contact details

Locations

TG Investigational Trial Site

Zagreb, 10000, Croatia
TG Therapeutics Investigational Trial Site

Pasadena, California, 91105, United States
TG Therapeutics Investigational Trial Site

Denver, Colorado, 80045, United States
TG Therapeutics Investigational Trial Site

Miami, Florida, 33136, United States
TG Therapeutics Investigational Trial Site

Tampa, Florida, 33612, United States
TG Therapeutics Investigational Trial Site

Northbrook, Illinois, 60062, United States
TG Therapeutics Investigational Trial Site

Kansas City, Kansas, 66160, United States
TG Therapeutics Investigational Trial Site

Detroit, Michigan, 48201, United States
TG Therapeutics Investigational Trial Site

Las Vegas, Nevada, 89106, United States
TG Therapeutics Investigational Trial Site

Teaneck, New Jersey, 07666, United States
TG Therapeutics Investigational Trial Site

Albuquerque, New Mexico, 87131, United States
TG Therapeutics Investigational Trial Site

Amherst, New York, 14266, United States
TG Therapeutics Investigational Trial Site

Columbus, Ohio, 43214, United States
TG Therapeutics Investigational Trial Site

Westerville, Ohio, 43081, United States
TG Therapeutics Investigational Trial Site

Knoxville, Tennessee, 37922, United States
TG Therapeutics Investigational Trial Site

Dallas, Texas, 75246, United States
TG Therapeutics Investigational Trial Site

Frisco, Texas, 75034, United States
TG Therapeutics Investigational Trial Site

Round Rock, Texas, 78681, United States
TG Therapeutics Investigational Trial Site

San Antonio, Texas, 78258, United States
TG Therapeutics Investigational Trial Site

Seattle, Washington, 98109, United States
TG Therapeutics Investigational Trial Site

Grodno, 230017, Belarus
TG Therapeutics Investigational Trial Site

Grodno, 320017, Belarus
TG Therapeutics Investigational Trial Site

Minsk, 220114, Belarus
TG Therapeutics Investigational Trial Site

Minsk, 220116, Belarus
TG Therapeutics Investigational Trial Site

Minsk, 220226, Belarus
TG Therapeutics Investigational Trial Site

Osijek, 31000, Croatia
TG Therapeutics Investigational Trial Site

Varaždin, 42000, Croatia
TG Therapeutics Investigational Trial Site

Tbilisi, 00112, Georgia
TG Therapeutics Investigational Trial Site

Tbilisi, 00114, Georgia
TG Therapeutics Investigational Trial Site

Tbilisi, 00159, Georgia
TG Therapeutics Investigational Trial Site

Tbilisi, 00160, Georgia
TG Therapeutics Investigational Trial Site

Tbilisi, 00172, Georgia
TG Therapeutics Investigational Trial Site

Tbilisi, 00179, Georgia
TG Therapeutics Investigational Trial Site

Katowice, 40-555, Poland
TG Therapeutics Investigational Trial Site

Katowice, 40-568, Poland
TG Therapeutics Investigational Trial Site

Katowice, 40-684, Poland
TG Therapeutics Investigational Trial Site

Krakow, 31-505, Poland
TG Therapeutics Investigational Trial Site

Lodz, 41-800, Poland
TG Therapeutics Investigational Trial Site

Olsztyn, 10-561, Poland
TG Therapeutics Investigational Trial Site

Poznan, 61-583, Poland
TG Therapeutics Investigational Trial Site

Warsaw, 04-141, Poland
TG Therapeutics Investigational Trial Site

Zabrze, 04-749, Poland
TG Therapeutics Investigational Trial Site

Arkhangelsk, 163045, Russia
TG Therapeutics Investigational Trial Site

Barnaul, 656045, Russia
TG Therapeutics Investigational Trial Site

Bryansk, 241033, Russia
TG Therapeutics Investigational Trial Site

Chelyabinsk, 454021, Russia
TG Therapeutics Investigational Trial Site

Kemerovo, 650066, Russia
TG Therapeutics Investigational Trial Site

Krasnoyarsk, 660037, Russia
TG Therapeutics Investigational Trial Site

Kursk, 305007, Russia
TG Therapeutics Investigational Trial Site

Moscow, 125367, Russia
TG Therapeutics Investigational Trial Site

Moscow, 127015, Russia
TG Therapeutics Investigational Trial Site

Nizhny Novgorod, 603155, Russia
TG Therapeutics Investigational Trial Site

Novosibirsk, 630007, Russia
TG Therapeutics Investigational Trial Site

Novosibirsk, 630087, Russia
TG Therapeutics Investigational Trial Site

Pyatigorsk, 357538, Russia
TG Therapeutics Investigational Trial Site

Saint Petersburg, 197002, Russia
TG Therapeutics Investigational Trial Site

Saint Petersburg, 197110, Russia
TG Therapeutics Investigational Trial Site

Saint Petersburg, 197376, Russia
TG Therapeutics Investigational Trial Site

Saransk, 430032, Russia
TG Therapeutics Investigational Trial Site

Smolensk, 214018, Russia
TG Therapeutics Investigational Trial Site

Tomsk, 634050, Russia
TG Therapeutics Investigational Trial Site

Tyumen, 625000, Russia
TG Therapeutics Investigational Trial Site

Ufa, 450005, Russia
TG Therapeutics Investigational Trial Site

Yekaterinburg, 620102, Russia
TG Therapeutics Investigational Trial Site

Belgrade, 11000, Serbia
TG Therapeutics Investigational Trial Site

Kragujevac, 34000, Serbia
TG Therapeutics Investigational Trial Site

Cherkasy, 18009, Ukraine
TG Therapeutics Investigational Trial Site

Chernihiv, 14001, Ukraine
TG Therapeutics Investigational Trial Site

Chernihiv, 14029, Ukraine
TG Therapeutics Investigational Trial Site

Chernivtsi, 58002, Ukraine
TG Therapeutics Investigational Trial Site

Ivano-Frankivsk, 76008, Ukraine
TG Therapeutics Investigational Trial Site

Kharkiv, 61058, Ukraine
TG Therapeutics Investigational Trial Site

Kharkiv, 61103, Ukraine
TG Therapeutics Investigational Trial Site

Kharkiv, 61176, Ukraine
TG Therapeutics Investigational Trial Site

Kyiv, 03037, Ukraine
TG Therapeutics Investigational Trial Site

Kyiv, 03115, Ukraine
TG Therapeutics Investigational Trial Site

Lviv, 79000, Ukraine
TG Therapeutics Investigational Trial Site

Lviv, 79010, Ukraine
TG Therapeutics Investigational Trial Site

Odesa, 65009, Ukraine
TG Therapeutics Investigational Trial Site

Poltava, 36011, Ukraine
TG Therapeutics Investigational Trial Site

Ternopil, 46027, Ukraine
TG Therapeutics Investigational Trial Site

Uzhhorod, 88018, Ukraine
TG Therapeutics Investigational Trial Site

Vinnytsia, 21005, Ukraine
TG Therapeutics Investigational Trial Site

Zaporizhia, 69065, Ukraine
TG Therapeutics Investigational Trial Site

Zaporizhia, 96900, Ukraine
TG Therapeutics Investigational Trial Site

Zhytomyr, 10002, Ukraine